Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes
Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes
复制标题
DOI：
10.2337/diacare.26.9.2628
复制
发表时间：
2003-09-01
期刊：
影响因子：
16.2
通讯作者：
Levy, AP
中科院分区：
文献类型：
--
作者：
Roguin, A;Koch, W;Levy, AP
目的-本研究的目的是确定是否结合珠蛋白（Hp）基因型是预测再狭窄和主要不良心脏事件（MACE）后，经皮腔内冠状动脉成形术（PTCA）在个体diabetes.RESEARCH设计和方法-一个连续系列的935名糖尿病患者接受口服药物和/或胰岛素治疗后，我一年的PTCA。主要研究终点为血管造影再狭窄、MACE，次要研究终点定义为靶血管血运重建、心肌梗死和死亡。在Hp基因座存在两个等位基因，表示为1和2。Hp基因型（Hp 1-1，Hp 2-1，或Hp 2-2）通过PCR.RESULTS确定-在控制所有已知的决定因素的多变量分析结果后，PTCA，我们发现，Hp基因型是一个非常显着的独立预测MACEs在I年期后，在糖尿病患者PTCA。这主要是由于在此期间心肌梗死风险的差异：Hp 1-1，129例中0例（0%）; Hp 2-1，424例中20例（4.7%）;和Hp 2-2，32/382（8.4%）; P <0.0001。结论：Hp基因型似乎是不良心脏事件的高度预测因子，尤其是心肌梗死，在PTCA术后1年内。Hp基因型的确定可能有助于评估新的治疗方法，以降低PTCA后心血管疾病的风险。
OBJECTIVE - The goal of this study was to determine whether the haptoglobin (Hp) genotype was predictive of restenosis and major adverse cardiac events (MACEs) after percutaneous transluminal coronary angioplasty (PTCA) in individuals with diabetes.RESEARCH DESIGN AND METHODS - A consecutive series of 935 diabetic patients treated with oral agents and/or insulin were followed for I year after PTCA. The primary study end point was angiographic restenosis, MACEs and secondary study end points were defined as target vessel revascularization, myocardial infarction, and death. Two alleles exist at the Hp gene locus, denoted 1 and 2. The Hp genotype (Hp 1-1, Hp 2-1, or Hp 2-2) was determined by PCR.RESULTS - in multivariate analysis controlling for all known determinants of outcome after PTCA, we found that the Hp genotype was a highly significant independent predictor of MACEs in the I-year period after PTCA in individuals with diabetes. This was predominantly due to differences in the risk of myocardial infarction during that period: Hp 1-1, 0 of 129 (0%); Hp 2-1, 20 of 424 (4.7%); and Hp 2-2, 32 of 382 (8.4%); P < 0.0001.CONCLUSIONS - The Hp genotype seems to be highly predictive of adverse cardiac events, particularly myocardial infarction, in the 1-year period after PTCA. Determination of the Hp genotype may be useful in the evaluation of new therapies to reduce cardiovascular risk after PTCA.